Market Data 
Markets
Replies to post #12611 on Moderna Inc (MRNA)
04/16/23 6:29 PM
December’s toplining of the first ever positive results from a controlled trial of a cancer immunotherapy, Moderna’s mRNA-4157, caused jubilation [#msg-170681303, #msg-170681207]. The group’s valuation gained $15bn, and the news validated Merck & Co’s earlier $250m bet on the project.
But was the enthusiasm warranted? The answer, after full data from the Keynote-942 trial in adjuvant melanoma were unveiled at AACR today, seems to be: maybe.
…At AACR it was revealed that the RFS rates at 18 months were 78.6% for the immunotherapy combo [i.e. mRNA-1427 + Keytruda], versus 62.2% for Keytruda alone. Severe adverse events occurred in 25% versus 18% of patients respectively…
…The RFS result cut at 12 months came out at 77% for control and 83% for Keytruda plus mRNA-4157…
…Moderna said a phase 3 melanoma trial would begin soon, with studies in "lung cancer and beyond" also planned.
AI
